Source comparison

Tesamorelin vs Other GH-Releasing Peptides

Tesamorelin is one of several peptides that increase growth hormone levels. Each works through a different mechanism, and the choice depends on your goals, budget, and risk tolerance. For a comprehensive comparison of all peptides used for body composition, se

This comparison does not assign a generated winner or score.

Tesamorelin is one of several peptides that increase growth hormone levels. Each works through a different mechanism, and the choice depends on your goals, budget, and risk tolerance. For a comprehensive comparison of all peptides used for body composition, see our best peptides for weight loss guide.

More references

Related material

Comparison

Tesamorelin vs CJC-1295/Ipamorelin

CJC-1295 (with DAC) is a modified GHRH analog with a dramatically longer half-life (5 to 8 days) due to its Drug Affinity Complex. It is often combined with ipamorelin, a growth h…

View details →

Comparison

Tesamorelin vs Exogenous Growth Hormone

The distinction matters clinically. Exogenous GH (somatropin) delivers a fixed dose that bypasses the pituitary entirely. This often raises IGF-1 levels above the physiological ra…

View details →

Comparison

Tesamorelin vs Retatrutide and GLP-1 Agonists

Tesamorelin and GLP-1 agonists reduce body fat through entirely different pathways. Comparing them directly is like comparing a scalpel to a sledgehammer: both remove material, bu…

View details →

Comparison

Tesamorelin vs Sermorelin

Sermorelin is the first 29 amino acids of natural GHRH. It was FDA-approved for pediatric growth hormone deficiency (brand name Geref) but was discontinued in 2008 for commercial …

View details →

Comparison

Egrifta SV® vs Egrifta WR™: What’s Changed

In 2024, the manufacturer Theratechnologies introduced a new formulation called Egrifta WR™, designed for more convenient dosing. Formulation Daily Dose Volume Reconstitution Adva…

View details →

Comparison

Continuous use versus cycling: what the trials documented

The community 8-on/8-off pattern is one approach; the clinical record describes another. In the Phase 3 program, tesamorelin was dosed at 2 mg subcutaneously every day for 52 cont…

View details →